For example, doxorubicin (DOX) combined with the indoleamine 2,3-dioxygenase (IDO-1) inhibitor indoximod (IND) exhibited a synergistic antitumor response that was superior to a DOX-only treatment in 4T1 orthotopic tumor-bearing mice [65]. The gene discussed is IDO1; the disease is neoplasm.